Core Component D: Gastrdenterology, Pulmonary, and Nephrology Services The overall objective of Core D is to enhance the quality of the clinical research studies conducted throughout the program project;it is critical to and highly integrated with the .
specific aims of Projects 1, 2, 3, 5, and 6. Specifically, the Core staff are involved in initial protocol review and participate in the definition of gastrointestinal, hepatic, pulmonary, and renal study endpoints, ensuring standardized patient evaluations, specimen collection, and interpretation. Both the Gastroenterology/Hepatology and Pulmonary programs have had a presence at the FHCRC for 30 years;their faculty, research nurses, and technicians have as their sole activity the care of transplant patients and support of FHCRC research activities. The addition of Nephology services broadens the Core services provided to Project investigators. Both acute and chronic kidney disease affect the outcome of patients enrolled in protocols described in this grant. The personnel of this Core have extensive experience in evaluating organ dysfunction in patients undergoing hematopoietic cell transplant. Through the organization of the Core, highly accurate data are supplied to investigators at a cost saving because of economies of scale. Facilities include in-patient and out-patient endoscopy suites, dedicated subspecialty clinic areas for transplant patients, a Pulmonary Function Laboratory specifically for transplant patients, and centralized computer systems for access to and storage of clinical and research data. The Core staff have an ongoing and very effective interaction with Biostatistics (Core A), Pathology (Core B), Microbiology and Virology (Core C), and Long-term Follow-up (Core F) faculty, staff, and laboratories. Working closely with transplant physicians and investigators, the Core members have developed large cross-relational databases generated from both research and clinical assessments. This database has become an extremely valuable resource for retrospective analysis and hypothesis testing and is highly integrated with Biostatistics so that data are available to all FHCRC investigators. This Core provides state-of-the art care for patients being treated for their underlying leukemia. Relevance to public health: The projects described in this grant are intended to cure cancer, specifically cancers, involving the blood, commonly known as leukemias. The methods that will be used to cure leukemia may have side effects that involve the gastrointestinal tract, liver, lungs, and kidneys. This Core component has as its goal the prevention and treatment of these side-effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-35
Application #
8073194
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
35
Fiscal Year
2010
Total Cost
$64,020
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562

Showing the most recent 10 out of 1845 publications